Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24559094 | 0.80 | HPGD (1.00) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL24559159 | 0.75 | CYP2C9 (0.74) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL515968 | 0.75 | CYP3A4 (0.75) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL515969 | 0.74 | POLB (0.61) | CYP3A4HSD17B10ALDH1A1POLBMEN1 | |
| SCHEMBL14693698 | 0.73 | LMNA (0.54) | CYP1A2CYP3A4HSD17B10ALDH1A1POLB | |
| SCHEMBL24559445 | 0.73 | MEN1 (0.57) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL515533 | 0.72 | CYP3A4 (0.62) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL4226651 | 0.72 | CYP3A4 (0.51) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL24667106 | 0.71 | CYP2C9 (0.52) | CYP2C9CYP1A2CYP3A4HPGDALOX15 | |
| SCHEMBL24559138 | 0.70 | CYP1A2 (0.58) | CYP2C9CYP1A2CYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871751-B2 | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871751-B2 | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-11-26 | — | — | US | disclosed |
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-11-26 | — | — | US | disclosed |
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291972-A1 | Compositions and Methods Relating to Nuclear Hormone and Steroid Hormone Receptors Including Inhibitors of Estrogen Receptor Alpha-mediated Gene Expression and Inhibition of Breast Cancer | PGR, ESR1, CYP19A1 | CYP2C9 1043/4885CYP1A2 137/4885CYP3A4 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.